Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesViatris Inc

Viatris Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
21.175 USD 0.12 ( 0.55%)
Last update at 2026-11-12T15:52:00Z
VOLUME
1520697
Market Cap
19124.04M

Momentum Score

…

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
20.88
Low
21.20
High
52 Week Price Range
9.11
Low
18.25
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Viatris is a global pharmaceutical company formed from Mylan and Pfizer’s Upjohn business that develops, manufactures and distributes generic and branded medicines. Long-term growth drivers include demographic demand for affordable medicines, expansion in emerging markets and potential cost and portfolio optimization from its integrated manufacturing and distribution network. These factors may make the company attractive to investors seeking diversified exposure to off-patent and specialty pharmaceuticals.
Major risks include steep pricing competition, patent and product litigation, regulatory and manufacturing compliance across jurisdictions and significant indebtedness that may limit flexibility.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
21.06
Dividend Yield
2.88%
Revenue TTM
14737.30M
Revenue Per Share
12.71
Gross Profit TTM
5940.20M
Debt / Equity
1.00
ROE
-2.75%
Net Debt
13353.40M
ROCE
-10.61%
Diluted EPS TTM
-0.37

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -3665.00M -623.20M 202.90M 2813.20M -664.40M
Net income -3514.90M -634.20M 54.70M 2078.60M -1269.10M
Selling general administrative 3794.10M 4425.60M 4309.70M 4179.10M 4529.20M
Gross profit 5013.50M 5623.60M 6438.60M 6497.00M 5575.50M
Reconciled depreciation 2798.30M 2893.20M 2965.90M 3027.60M 4506.50M
Ebit -3193.70M -73.20M 776.00M 418.80M -4205.50M
Ebitda -395.40M 2820.00M 3516.50M 3446.40M 301.00M
Depreciation and amortization 2798.30M 2893.20M 2740.50M 3027.60M 4506.50M
Operating income -2663.10M 10.10M 766.20M 418.80M -4205.50M
Other operating expenses 16963.00M 14729.20M 14660.70M 14607.00M 17591.10M
Interest expense 471.30M 550.00M 573.10M 592.40M 636.20M
Tax provision -150.10M 11.00M 695.30M 734.60M 604.70M
Net interest income -471.30M -550.00M -579.30M -592.40M -636.20M
Income tax expense -150.10M 11.00M 148.20M 734.60M 604.70M
Total revenue 14299.90M 14739.30M 15426.90M 16262.70M 17886.30M
Total operating expenses 7676.60M 5613.50M 5672.40M 4841.30M 5280.30M
Cost of revenue 9286.40M 9115.70M 8988.30M 9765.70M 12310.80M
Total other income expense net -1001.90M -633.30M -563.30M 2394.40M 3541.10M
Net income from continuing ops -3514.90M -634.20M 1831.50M 2078.60M -1269.10M
Net income applicable to common shares - - - 2078.60M -1269.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 37193.10M 41500.90M 47685.50M 50022.20M 54842.80M
Intangible assets 15102.10M 17070.90M 19181.10M 22607.10M 26134.20M
Other current assets 420.20M 1054.70M 3638.60M 1811.20M 1957.60M
Total liab 22481.80M 22865.40M 27218.10M 28949.90M 34350.10M
Total stockholder equity 14711.30M 18635.50M 20467.40M 21072.30M 20492.70M
Other current liab 3757.90M 4143.70M 4142.80M 3403.20M 8006.90M
Common stock 12.50M 12.30M 12.20M 12.10M 12.10M
Capital stock 12.50M 12.30M 12.20M 12.10M 12.10M
Retained earnings -388.30M 3418.80M 4639.70M 5175.60M 3688.80M
Other liab - - - 4007.10M 4547.70M
Good will 6754.70M 9133.30M 9867.10M 10425.80M 12113.70M
Other assets - - - 2976.10M 5692.00M
Cash 1348.00M 734.80M 993.60M 1259.90M 701.20M
Total current liabilities 7094.30M 5779.40M 7777.40M 6746.20M 9884.40M
Current deferred revenue - -279.80M 226.80M 925.90M -1056.10M
Net debt 13353.40M 13571.10M 17386.30M 18014.40M 20893.40M
Short term debt 2042.70M 87.70M 2026.40M 1259.10M 1877.50M
Short long term debt 1929.90M 0.60M 1934.70M 1250.50M 1877.50M
Short long term debt total 14701.40M 14305.90M 18379.90M 19274.30M 21594.60M
Other stockholder equity 17794.10M 18417.30M 18562.90M 18645.80M 18536.10M
Property plant equipment - - - 3283.80M 3479.40M
Total current assets 9220.90M 9520.70M 12228.80M 10635.40M 10902.90M
Long term investments 815.00M 1349.80M 1142.00M 1091.40M 0.00M
Net tangible assets - - - -11960.60M -17755.20M
Short term investments 106.40M 355.10M 86.30M 212.60M 233.80M
Net receivables 3347.10M 3522.00M 4040.60M 3814.50M 4266.40M
Long term debt 12480.60M 14038.90M 16188.10M 18015.20M 19717.10M
Inventory 3999.20M 3854.10M 3469.70M 3519.50M 3977.70M
Accounts payable 1293.70M 1355.30M 1381.40M 1158.00M 1056.10M
Accumulated other comprehensive income -2707.00M -3212.90M -2747.40M -2761.20M -1744.30M
Non currrent assets other 1353.90M 754.00M 1568.40M 1052.80M 5692.00M
Non current assets total 27972.20M 31980.20M 35456.70M 39386.80M 43939.90M
Capital lease obligations 287.50M 266.40M 248.40M 262.00M 287.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 1800.70M 904.60M 1520.50M -0.40M
Change to liabilities - - - 170.20M -70.40M
Total cashflows from investing activities -427.70M 1800.70M -764.10M 1520.50M -117.80M
Net borrowings 0.10M -3713.70M -1249.60M -3280.10M -2099.10M
Total cash from financing activities -1293.90M -4330.40M -2301.90M -3877.90M -3012.00M
Change to operating activities - - - -618.30M -666.50M
Net income -3514.90M -634.20M 54.70M 2078.60M -1269.10M
Change in cash 611.90M -257.50M -268.90M 556.30M -143.80M
Begin period cash flow 736.10M 993.60M 1262.50M 706.20M 850.00M
End period cash flow 1348.00M 736.10M 993.60M 1262.50M 706.20M
Total cash from operating activities 2315.90M 2302.90M 2799.60M 2952.60M 3016.90M
Issuance of capital stock 2.60M 2.50M 3.30M 3.30M -
Depreciation 2798.30M 2708.50M 2740.50M 3027.60M 4506.50M
Other cashflows from investing activities -48.90M 2476.70M 280.60M - -
Dividends paid 561.20M 574.80M 575.60M 581.60M 399.00M
Change to inventory -106.40M -723.40M -613.30M -259.50M -427.60M
Change to account receivables 334.60M 300.10M 78.60M -240.30M 59.30M
Sale purchase of stock -500.50M -250.00M -250.00M - -
Other cashflows from financing activities -234.90M 205.60M -229.80M 362.90M 1588.30M
Change to netincome - - - -1057.50M 2877.10M
Capital expenditures 378.80M 326.00M 474.50M 443.00M 509.40M
Change in working capital -2504.30M -318.60M -711.30M -922.60M -1804.80M
Stock based compensation 177.70M 146.10M 180.70M 116.40M 111.20M
Other non cash items 5835.60M 1168.70M 922.10M -1321.50M 797.40M
Free cash flow 1937.10M 1976.90M 2325.10M 2509.60M 2507.50M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VTRS
Viatris Inc		 0.12
0.55%		 21.18 - 6.20 1.30 1.34 2.12 11.92
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Viatris Inc

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Robert J. Coury Global Center, Canonsburg, PA, United States, 15317

724 514 1800

https://www.viatris.com

30000

Name Title Year Born
Mr. Robert J. Coury Exec. Chairman 1961
Mr. Michael Goettler CEO & Exec. Director 1968
Mr. Rajiv Malik Pres & Exec. Director 1961
Mr. Sanjeev Narula Chief Financial Officer 1961
Mr. Anthony Mauro Pres of Developed Markets 1973
Mr. Sanjeev Kumar Sethi Chief Operating Officer 1967
Mr. Paul B. Campbell Chief Accounting Officer, Sr. VP & Corp. Controller 1967
Ms. Melissa Trombetta Head of Global Investor Relations NA
Mr. Brian S. Roman Global Gen. Counsel 1970
Mr. David Bayles Chief Compliance Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…